Stockpiled Ebola vaccines make antibodies against the strain spreading in Congo

While an outbreak of Bundibugyo virus disease has spread across five provinces of the Democratic Republic of the Congo without an approved vaccine or treatment of its own, researchers examining leftover blood samples from an earlier, unrelated West African vaccine trial have found something relevant to the emergency underway: both licensed Ebola vaccines produce antibodies that bind Bundibugyo virus, a different ebolavirus species entirely [s1].

The finding, published as a letter in the New England Journal of Medicine on 22 July, does not show that either vaccine protects against Bundibugyo virus disease. It shows that the immune response these vaccines generate is not as narrowly targeted as the vaccines' original design intended.

Where the samples came from

The analysis draws on 179 blood samples collected during PREVAC, a large clinical trial conducted in West Africa that evaluated Ebola vaccine regimens in adults and children. None of the trial's original purpose concerned Bundibugyo virus; PREVAC tested vaccines built against Zaire ebolavirus, the species responsible for the 2014-2016 West African epidemic and several of DRC's more recent outbreaks. The researchers behind this new analysis went back to stored PREVAC samples specifically to test whether antibodies raised against Zaire ebolavirus would also recognize the more distantly related Bundibugyo species — a question that became newly urgent once Bundibugyo virus disease began spreading in DRC this year [s1].

Two vaccine regimens were represented in the samples: the single-dose rVSV-based vaccine, including samples collected after a booster dose, and the two-dose Ad26.MVA regimen [s1]. Both are licensed and have been used in prior Zaire ebolavirus outbreak responses.

What the antibody testing showed

Using a multiplex assay designed to detect antibody binding across multiple ebolavirus antigens simultaneously, the researchers found cross-reactive antibody responses against Bundibugyo virus in recipients of both vaccine regimens [s1]. The response was consistently weaker than each vaccine's response against Zaire ebolavirus, the species it was actually designed to target, but it was detectable and, in most participants, sustained over time [s1].

The two regimens showed somewhat different timelines. Among rVSV recipients, cross-reactive antibodies were detectable by 28 days after vaccination and remained present at three months [s1]. Among Ad26.MVA recipients — a regimen that itself involves two sequential doses — the cross-reactive response strengthened between the one-month and three-month sampling points [s1]. The pattern held across both adults and children in the sample [s1].

Why "detectable" is not the same as "protective"

This is the distinction the study's own authors are careful about, and it is the one most likely to get lost in translation as the finding moves from a specialist correspondence into wider discussion during an active outbreak. Binding antibodies — antibodies that physically attach to a viral antigen in a lab assay — are necessary but not sufficient evidence of protection. Neutralizing antibodies, which block viral entry into cells, and broader immune mechanisms including T-cell responses, typically matter more for whether a vaccine actually prevents or attenuates disease. This analysis characterizes binding antibody responses; it does not report neutralization data against live or pseudotyped Bundibugyo virus, nor any clinical outcome data, because none of the PREVAC participants were ever exposed to Bundibugyo virus.

The result is consistent with earlier findings in nonhuman primates, where Zaire ebolavirus vaccination produced partial heterologous protection against Bundibugyo virus challenge — protection that was real but incomplete compared with matched-species vaccination. Whether the human antibody levels observed here reach a threshold associated with even partial protection is, at this point, unknown.

Why it matters anyway, right now

In the absence of any Bundibugyo-specific vaccine, and with WHO having convened expert groups to assess candidate countermeasures for the current outbreak, evidence that existing, already-manufactured, already-licensed Zaire ebolavirus vaccines generate any cross-reactive immune response at all is practically relevant. It supports the case for evaluating stockpiled vaccines as an outbreak-response tool while purpose-built Bundibugyo countermeasures remain in earlier stages of development — not because this data proves they would work, but because it does not rule the possibility out, and the alternative is no vaccine option of any kind.

What to watch

Whether follow-up studies test neutralizing antibody activity specifically against Bundibugyo virus, rather than binding activity alone, which would be a stronger signal of potential protection. Whether WHO's expert groups incorporate this finding into their assessment of candidate countermeasures for the active DRC outbreak. And whether any decision is made to deploy existing Zaire ebolavirus vaccines off-label in the outbreak response before that stronger evidence exists — a decision that would weigh uncertain benefit against the vaccines' already-established safety profile. This article describes laboratory findings, not a treatment or vaccination recommendation.

Sources

• [s1] Lhomme E, Wiedemann A, Ayouba A, et al., for the PREVAC Study Team, "Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines," New England Journal of Medicine, 22 July 2026. https://doi.org/10.1056/nejmc2608018